Loading
LCB02A is an experimental monoclonal antibody from LigaChem Biosciences in phase 2 trials, aimed at Claudin 18.2.
LCB02A is a monoclonal antibody developed by LigaChem Biosciences. Its target is Claudin 18.2. ClinicalTrials.gov describes the intervention as: CLDN18.2-directed human monoclonal antibody (Ab) linked to a topoisomerase I inhibiting payload. It is the investigational product in 1 recruiting or active industry-led phase 2 and phase 3 interventional cancer trial. The largest, NCT07460375, plans to enrol 191 participants with primary completion expected 2030-02. Status reflects the highest phase registered on ClinicalTrials.gov; no efficacy results are recorded here.
Monoclonal antibody directed at Claudin 18.2, as stated in the ClinicalTrials.gov intervention record; the detailed mechanism is not stated. Connects to Claudin 18.2.
1.LCB02A binds Claudin 18.2.
Country and place are remembered in this browser only. A postcode is sent to OpenStreetMap's Nominatim service to find coordinates when you press the button; nothing else leaves your device.
Query for this drug: (TITLE:"LCB02A" OR ABSTRACT:"LCB02A") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about LCB02A, not a curated reading list.
Shares LigaChem Biosciences and the tag pipeline.
Shares LigaChem Biosciences and the tag pipeline.
Shares Claudin 18.2 and the tag pipeline.
Shares Claudin 18.2 and the tag pipeline.
Shares Claudin 18.2 and the tag pipeline.
Shares Claudin 18.2 and the tag pipeline.
Shares Claudin 18.2 and the tag pipeline.
Shares Claudin 18.2 and the tag pipeline.